N-of-1 trials are single-patient clinical trials that use within-subject crossover designs to determine optimal treatment for an individual patient. This methodology is particularly relevant for rare diseases like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), where traditional clinical trials are challenging due to limited patient populations.
N-of-1 trials offer a rigorous approach to personalizing treatment by systematically comparing interventions within a single patient. This approach addresses the critical need for evidence-based treatment decisions in atypical parkinsonism, where standard RCT data may be unavailable or inapplicable[1].
# Conceptual Bayesian N-of-1 analysis
def analyze_nof1(data):
# data: list of (period, treatment, outcome) tuples
posterior_A = update_prior(data, treatment='A')
posterior_B = update_prior(data, treatment='B')
prob_A_better = probability(posterior_A > posterior_B)
return {
'P(A>B)': prob_A_better,
'treatment_effect': posterior_A.mean() - posterior_B.mean()
}
Why Washout Matters:
Washout Duration Guidelines:
| Treatment Class | Minimum Washout |
|---|---|
| Cholinesterase inhibitors | 2 weeks |
| Dopamine agonists | 1 week |
| MAO-B inhibitors | 2 weeks |
| Antidepressants | 4 weeks |
| Supplements | 1 week |
Duan N, et al. N-of-1 trials: A method for personalized therapeutic assessment. 2022. ↩︎
Zucker DR, et al. Bayesian meta-analysis of N-of-1 trials. 2010. ↩︎